Patents by Inventor Eduardo Pénton Arias

Eduardo Pénton Arias has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210187101
    Abstract: The present invention relates to a rhinovaccination system for preventing and treating hepatitis B, comprising a hepatitis B vaccine composition for administration to nasal mucosa in combination with a medical nozzle device.
    Type: Application
    Filed: June 4, 2019
    Publication date: June 24, 2021
    Inventors: Taizou KAMISHITA, Takashi MIYAZAKI, Yoichi HIASA, Fazle Akbar SHEIKH MOHAMMAD, Osamu YOSHIDA, Julio Cesar AGUILAR RUBIDO, Gerardo Enrique GUILLEN NIETO, Eduardo PENTON ARIAS
  • Publication number: 20200297840
    Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.
    Type: Application
    Filed: March 14, 2017
    Publication date: September 24, 2020
    Inventors: Julio César AGUILAR RUBIDO, Yadira LOBAINA MATO, Enrique IGLESIAS PEREZ, Eduardo PENTÓN ARIAS, Gerardo Enrique GUILLÉN NIETO, Jorge Agustín AGUIAR SANTIAGO, Sonia GONZALEZ BLANCO, Jorge VALDES HERNANDEZ, Mariela VAZQUEZ CASTILLO
  • Publication number: 20170119733
    Abstract: The present invention describes peptides comprising phycocyanobilin (PCB), as well as the medical use of said peptides and that of PCB, due to the neuroprotector and/or neuroregenerative effects identified for them. Furthermore, pharmaceutical combinations of said peptides and of PCB with proteins or other peptides with synergic effect justify their use for ischemic or neurodegenerative CNS disease treatment.
    Type: Application
    Filed: November 10, 2016
    Publication date: May 4, 2017
    Inventors: Giselle Penton Rol, Alexey Llopiz Arzuaga, Javier Marin Prida, Eduardo Penton Arias, Efrain Rodriguez Jimenez, Alexis Musacchio Lasa, Vladimir Armando Besada Perez, Gilberto Lazaro Pardo Andreu, Luis Javier Gonzalez Lopez, Nancy Pavon Fuentes, Gerardo Enrique Guillen Nieto, Pedro Antonio Lopez Saura
  • Patent number: 9518085
    Abstract: The present invention describes peptides comprising phycocyanobilin (PCB), as well as the medical use of said peptides and that of PCB, due to the neuroprotector and/or neuroregenerative effects identified for them. Furthermore, pharmaceutical combinations of said peptides and of PCB with proteins or other peptides with synergic effect justify their use for ischemic or neurodegenerative CNS disease treatment.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: December 13, 2016
    Assignee: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECHNOLOGÍA
    Inventors: Giselle Penton Rol, Alexey Llopiz Arzuaga, Javier Marin Prida, Eduardo Penton Arias, Efrain Rodriguez Jimenez, Alexis Musacchio Lasa, Vladimir Armando Besada Perez, Gilberto Lazaro Pardo Andreu, Luis Javier Gonzalez Lopez, Nancy Pavon Fuentes, Gerardo Enrique Guillen Nieto, Pedro Antonio Lopez Saura
  • Publication number: 20140356319
    Abstract: The present invention describes peptides comprising phycocyanobilin (PCB), as well as the medical use of said peptides and that of PCB, due to the neuroprotector and/or neuroregenerative effects identified for them. Furthermore, pharmaceutical combinations of said peptides and of PCB with proteins or other peptides with synergic effect justify their use for ischemic or neurodegenerative CNS disease treatment.
    Type: Application
    Filed: June 29, 2012
    Publication date: December 4, 2014
    Applicant: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA
    Inventors: Giselle Penton Rol, Alexey Llopiz Arzuaga, Javier Marin Prida, Eduardo Pentón Arias, Efraín Rodríguez Jiménez, Alexis Musacchio Lasa, Vladimir Armando Besada Perez, Gilberto Lázaro Pardo Andreu, Luis Javier González López, Nancy Pavón Fuentes, Gerardo Enrique Guillen Nieto, Pedro Antonio López Saura
  • Publication number: 20120308615
    Abstract: The present invention is related with the field of the therapeutic immunization, specifically with the employment of a new formulation of antigens of the Hepatitis B Virus (HBV) for the cellular stimulation. The formulation is formed by the surface antigens (HBsAg) precipitated in suspension and the nucleocapsid (HBcAg) of the HBV. The formulation contains these antigens like suspended particles of sizes less than 500 nm and higher than 500 nm, in a mixture where the proportion among the particles of the mentioned sizes is among 50%-50% and 80%-20%, respectively. The selection of a range of sizes of particles allows that the levels of stimulation of several cellular types are maximized. Additionally, a cellular stimulation method is described with this formulation, and the later passive immunization of patients with chronic Hepatitis B, based on the maximum stimulation in vivo or in vitro using heterologous or autologous cells (dendritic cells, B cells and macrophages).
    Type: Application
    Filed: September 28, 2010
    Publication date: December 6, 2012
    Inventors: Julio César Aguilar Rubido, Yadira Lobaina Mato, Dunia Hernández Inguanzo, Heidy Trujillo Pérez, Freya de los Milagros Freyre Almeida, Verena Lucila Muzio González, Eduardo Pénton Arias, Sonia Gonzalez Blanco, Raimundo Ubieta Gómez, Gerardo Enrique Guillén Nieto, Luis Saturnino Herrera Martinez
  • Patent number: 8110182
    Abstract: The present invention consists of the combination of Interferon alpha and C-Phycocyanin (IFN-?/C-Phyco) for obtaining a pharmaceutical preparation for autoimmune disease, allergy and cancer treatments. The anti-inflammatory, immunomodulator, antioxidant, anti-viral, anti-proliferative and anti-tumoral effects, associated to the regulatory T cell inducer effect demonstrated in this invention is the rationale for the use of the IFN-?/C-Phyco combination in these diseases.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: February 7, 2012
    Assignee: Centro de Ingenieria Genectica y Biotecnologia
    Inventors: Giselle Penton Rol, Majel Cervantes Llanos, Eduardo Penton Arias, Diana Garcia del Barco Herrera, Carmen Maria Valenzuela Silva, Pedro Antonio Lopez Saura, Gerardo Enrique Guillen Nieto
  • Publication number: 20100093616
    Abstract: The present invention is directed to stimulate the neuroregeneration of the central nervous system due to autoimmune damage. In particular the pharmaceutical combination that comprise therapeutically effective concentrations of the Epidermal Growth Factor and the Growth Hormone Releasing Peptide-6, is administrated to a subject that suffers from symptoms of Multiple Sclerosis and Optic Neuromyelitis and corrects the demyelination caused by autoreactive cells in central nervous system.
    Type: Application
    Filed: February 24, 2006
    Publication date: April 15, 2010
    Inventors: Diana Garcia Del Barco Herrera, Gerardo Enrique Guillén Nieto, Jorge Amador Berlanga Acosta, Freya de los Milagros Freyre Almeida, Danay Cibrian Vera, Eduardo Pentón Arias
  • Publication number: 20090280087
    Abstract: The present invention consists of the combination of Interferon alpha and C-Phycocyanin (IFN-?/C-Phyco) for obtaining a pharmaceutical preparation for autoimmune disease, allergy and cancer treatments. The anti-inflammatory, immunomodulator, antioxidant, anti-viral, anti-proliferative and anti-tumoral effects, associated to the regulatory T cell inducer effect demonstrated in this invention is the rationale for the use of the IFN-?/C-Phyco combination in these diseases.
    Type: Application
    Filed: October 30, 2006
    Publication date: November 12, 2009
    Inventors: Giselle Penton Rol, Majel Cervantes Llanos, Eduardo Penton Arias, Diana Garcia del Barco Herrera, Carmen Maria Valenzuela Silva, Pedro Antonio Lopez Saura, Gerardo Enrique Guillen Nieto
  • Publication number: 20090104223
    Abstract: The invention relates to a method for obtaining aggregated antigenic structures that are capable of enhancing an immune response to aggregate antigens administered systemically and/or mucosally generating powerful immune response and to the chemical structures resulting from the application of said method, to the formulations obtained from such structures and their use. The method describes the obtention of novel aggregate antigenic structures by using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process. The aggregation state can also be provoket inside the yeast by changing incubation conditions.
    Type: Application
    Filed: October 10, 2007
    Publication date: April 23, 2009
    Inventors: Julio Cesar Aguilar Rubido, Eduardo Penton Arias, Dina Tleugabulova, Minerva Sewer Mensies, Verena Lucila Muzio Gonzalez, Gerardo Enrique Guillen Nieto, Iloki Assanga Simon Bernard, Luis Javier Cruz Ricondo, Viviana Falcon Cama, Yanet Tambara Hernandez
  • Patent number: 7374766
    Abstract: The present invention is related to the branch of medicine, particularly to the new formulations of vaccine antigens. The technical objective pursued with the present invention is, precisely, the development of formulations that are able to enhance the immune response to mucosally administered antigens, minimising the number of compounds in the formulation and generating strong mucosal and systemic responses through a synergic interaction between the antigens in the formulation. These formulations enable: a) to broaden the spectrum of the anti-hepatitis B immune response, containing as main compounds HBsAg and HBcAg, b) to enhance the response against HBsAg with a viral nucleocapsid c) to generate combined vaccines through the mucosal route with HBsAg as a central antigen. Stabilizers and preservatives can be introduced. The formulations of this invention can be applied in the pharmaceutical industry as human or veterinary vaccine formulations.
    Type: Grant
    Filed: December 1, 1999
    Date of Patent: May 20, 2008
    Assignee: Centro de Ingenieria Genetic y Biotechnologia
    Inventors: Julio César Aguilar Rubido, Daniel O. Palenzuela Gardón, Verena L. Muzio González, Gerardo E. Guillén Nieto, Eduardo Pentón Arias, Dagmara Pichardo Díaz, Enrique Iglesias Perez
  • Publication number: 20040202676
    Abstract: The present invention is related to the method for obtaining aggregated antigenic structures that are capable of enhancing an immune response to aggregate antigens administered systemically and/or mucosally generating powerful immune response and to the chemical structures resulting from the application of said method, to the formulations obtained from such structures and their use. The method describes the obtention of novel aggregate antigenic structures by using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process. The aggregation state can also be provoket inside the yeast by changing incubation conditions.
    Type: Application
    Filed: March 1, 2004
    Publication date: October 14, 2004
    Inventors: Julio Cesar Aguilar Rubido, Eduardo Penton Arias, Dina Tleugabulova, Minerva Sewer Mensies, Verena Lucila Muzio Gonzalez, Gerardo Enrique Guillen Nieto, Iloki Assanga Simon Bernard, Luis Javier Cruz Ricondo, Viviana Falcon Cama, Yanet Tambara Hernandez
  • Patent number: 6358933
    Abstract: The present invention is for a formulation comprising a nucleic acid vaccine and an immunoenhancing amount of acemannan, whereby the acemannan enhances immune response, in a host, to the vaccine. The present invention is also for a method of enhancing the immune response of a host to a nucleic acid vaccine by administering a formulation comprising a nucleic acid vaccine and acemannan.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: March 19, 2002
    Assignee: Centro de Ingenieria Genetica Y Biotechologia
    Inventors: Julio Cesar Aguilar Rubido, Verena Lucila Muzio Gonzalez, Gerardo Enrique Guillen Nieto, Eduardo Penton Arias, Maria de Jesus Leal Angulo, Dagmara Pichardo Diaz, Enrique Iglesias Perez, Antonieta Herrera Buch, Belquis Sandez Oquendo, Alexis Musacchio Lasa, Diogenes Quitana Vazquez, Lissere Crombet Menedez
  • Patent number: 6355414
    Abstract: The present invention is related to the field of medicine, particularly to the use of new adjuvant formulations with vaccine antigens. The technical objective pursued with this invention is, precisely, the development of formulations that are able to increase and/or modulate the immune response of the organism to vaccine antigens in the serum and the mucous lining. With this aim, a formulation was developed that contained as the main components the surface antigen of the hepatitis B virus and the acemannan in adequate proportions. As an extension of this result, formulations were developed in which a) HBsAg was used as the homologous or heterologous antigen carrier b) delivery systems of particulated antigens and c) soluble antigens, combined with the acemannan in specific proportions. The formulations of this invention are applicable in the pharmaceutical industry as vaccine formulations for human and veterinary use.
    Type: Grant
    Filed: January 6, 2000
    Date of Patent: March 12, 2002
    Assignee: Centro de Ingenieria Genetica y Biotechnologia
    Inventors: Julio Cesar Aguilar Rubido, Verena Lucila Muzio Gonzalez, Maria de Jesus Leal Angulo, Gerardo Enrique Guillen Nieto, Eduardo Penton Arias, Gloria Veliz Rios, Dagmara Pichardo Diaz, Antonieta Herrera Buch, Enrique Iglesias Perez, Luis Javier Cruz Ricondo, Tania Carmenate Portilla, Cirse Mesa Pardillo, Maydel Hechavarria Gay, Maylin Diaz Martinez, Juan Joel Madrazo Piñol